Sign in

    Nick Sherwood

    Research Analyst at Maxim Group

    Nick Sherwood is an Equity Research Associate at Maxim Group, specializing in biotechnology sector analysis with coverage of companies such as Pavmed Inc. While at Maxim Group, Sherwood has contributed to equity research focused on emerging biotech firms, noted for supporting direct company coverage and providing sector insights. He began his tenure at Maxim Group as an Equity Research Associate and there is no public record of prior industry positions. Sherwood’s professional credentials or securities licenses are not explicitly listed in available public records, and quantitative performance metrics or awards have not been reported.

    Nick Sherwood's questions to CUTR leadership

    Nick Sherwood's questions to CUTR leadership • Q1 2024

    Question

    Inquired about the long-term runway for AviClear's international expansion, the company's R&D innovation strategy, and requested more detail on the impact of GLP-1 drugs on the body contouring business.

    Answer

    The executive described a long runway for international expansion, with a gradual, multi-year rollout across different markets and territories. R&D efforts are focused on expanding the clinical applications of AviClear for new indications. Regarding GLP-1s, they acknowledged a near-term negative impact on the body contouring business but anticipate a future rebound as patients seek treatment for residual fat and skin laxity after weight loss.

    Ask Fintool Equity Research AI